Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination

Objective To evaluate seroreactivity and disease flares after COVID-19 vaccination in a multi-ethnic/racial cohort of patients with systemic lupus erythematosus (SLE). Methods 90 SLE patients and 20 healthy controls receiving a complete COVID-19 vaccine regimen were included. IgG seroreactivity to t...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis & Rheumatology 2021
Main Authors: Izmirly, Peter M, Kim, Mimi Y, Samanovic, Marie, Fernandez-Ruiz, Ruth, Ohana, Sharon, Deonaraine, Kristina K, Engel, Alexis J, Masson, Mala, Xie, Xianhong, Cornelius, Amber R, Herati, Ramin S, Haberman, Rebecca H, Scher, Jose U, Guttmann, Allison, Blank, Rebecca B, Plotz, Benjamin, Haj-Ali, Mayce, Banbury, Brittany, Stream, Sara, Hasan, Ghadeer, Ho, Gary, Rackoff, Paula, Blazer, Ashira D, Chung-E Tseng, Belmont, H Michael, Saxena, Amit, Mulligan, Mark J, Clancy, Robert M, Buyon, Jill P
Format: Web Resource
Language:English
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate seroreactivity and disease flares after COVID-19 vaccination in a multi-ethnic/racial cohort of patients with systemic lupus erythematosus (SLE). Methods 90 SLE patients and 20 healthy controls receiving a complete COVID-19 vaccine regimen were included. IgG seroreactivity to the SARS-CoV-2 spike receptor-binding domain (RBD) and SARS-CoV-2 microneutralization were used to evaluate B cell responses; IFN-γ production to assess T cell responses was measured by ELISpot. Disease activity was measured by the hybrid SLE disease activity index (SLEDAI) and flares were assigned by the SELENA/SLEDAI flare index. Results Overall, fully vaccinated SLE patients produced significantly lower IgG antibodies against SARS-CoV-2 spike RBD than controls. Twenty-six SLE patients (28.8%) generated an IgG response below that of the lowest control (
DOI:10.1002/art.41937